2-[(3,4-Dihydro-2-phenyl-2H-1-benzopyran-6-yl)oxy]-5-nitro-pyridine
2-[(3,4-Dihydro-2-phenyl-2H-1-benzopyran-6-yl)oxy]-5-nitro-pyridine 物理性質
- 沸点 :
- 515.1±50.0 °C(Predicted)
- 比重(密度) :
- 1.303±0.06 g/cm3(Predicted)
- 貯蔵温度 :
- room temp
- 溶解性:
- DMSO：可溶20mg/mL、透明
- 酸解離定数(Pka):
- -0.47±0.22(Predicted)
- 外見 :
- 粉
- 色:
- 白からベージュ
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| 主な危険性 |
T |
|
|
| Rフレーズ |
25 |
|
|
| Sフレーズ |
45 |
|
|
| RIDADR |
UN 2811 6.1 / PGIII |
|
|
| WGK Germany |
3 |
|
|
| 絵表示（GHS） |
|
| 注意喚起語 |
危険 |
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
| H301 |
飲み込むと有毒 |
急性毒性、経口 |
3 |
危険 |
|
P264, P270, P301+P310, P321, P330,P405, P501 |
| H413 |
長期的影響により水生生物に有害のおそれ |
水生環境有害性、慢性毒性 |
4 |
|
|
|
|
| 注意書き |
|
2-[(3,4-Dihydro-2-phenyl-2H-1-benzopyran-6-yl)oxy]-5-nitro-pyridine 価格
もっと(2)
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
Sigma-Aldrich Japan
|
SML0972 |
≥98% (HPLC)
ORM-10103 ≥98% (HPLC) |
488847-28-5 |
5mg |
￥28700 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
SML0972 |
≥98% (HPLC)
ORM-10103 ≥98% (HPLC) |
488847-28-5 |
25mg |
￥116000 |
2024-03-01 |
購入 |
2-[(3,4-Dihydro-2-phenyl-2H-1-benzopyran-6-yl)oxy]-5-nitro-pyridine 化学特性,用途語,生産方法
Biochem/physiol Actions
ORM-10103 is a potent, specific inhibitor of the Na(+)/Ca(2+) exchanger, NCX. The compound ORM-10103 inhibits both inward and outward NCX currents with IC50 values of 780 nM, and 960 nM, respectively. ORM-10103 blocks induced arrhythmias in canine cardiac tissue.
酵素阻害剤
This novel and specific sodium/calcium exchanger inhibitor (FW = 348.36 g/mol), also known as 5-nitro-2-(2-phenychroman-6-yloxy)pyridine, significantly reduces both the inward (EC50 = 780 nM) and outward (EC50 = 960 nM) currents of the electrogenic sodium-calcium exchanger (or NCX), without significantly change in the L-type Ca2+ current (or ICaL) or the maximum rate of depolarization (or dV/dtmax), indicative of the fast inward Na+ current. The NCX is widely expressed in different tissues. In heart, NCX plays an important role in calcium ion homeostasis, in excitationcontraction coupling, and in the electrophysiological properties of cardiac myocytes. ORM-10103 does not influence Na+/K+ pump or the main K+ currents of canine ventricular myocytes, but at 3 μM slightly diminishes the rapid delayed rectifier K+ current. Amplitudes of early and delayed afterdepolarizations were significantly decreased by ORM-10103 in a concentration-dependent manner. Such findings suggest that ORM-10103 can abolish triggered arrhythmias and may have antiarrhythmic electrophysiological properties. Other NCX inhibitors include: KB-R7943, SEA0400, SN-6, and YM-244769, but KB-R7943 and SEA-0400 also inhibit the ICaL, leaving the interpretation of their antiarrhythmic effects less certain.
2-[(3,4-Dihydro-2-phenyl-2H-1-benzopyran-6-yl)oxy]-5-nitro-pyridine 上流と下流の製品情報
原材料
準備製品
2-[(3,4-Dihydro-2-phenyl-2H-1-benzopyran-6-yl)oxy]-5-nitro-pyridine 生産企業
Global( 8)Suppliers
- 488847-28-5
- 2-[(3,4-Dihydro-2-phenyl-2H-1-benzopyran-6-yl)oxy]-5-nitro-pyridine
- ORM-10103
- 5-nitro-2-[(2-phenyl-3,4-dihydro-2H-chromen-6-yl)oxy]pyridine
- Pyridine, 2-[(3,4-dihydro-2-phenyl-2H-1-benzopyran-6-yl)oxy]-5-nitro-
- ORM-10103 >=98% (HPLC)
- ORM 10103,ORM10103